PubRank

N J Dimmock

Author PubWeight™ 120.24‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes. Cell 1985 3.36
2 Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J Gen Virol 1971 2.59
3 Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures. Virology 1967 2.41
4 Mechanisms of neutralization of animal viruses. J Gen Virol 1984 2.16
5 Review article initial stages in infection with animal viruses. J Gen Virol 1982 1.87
6 Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol 1986 1.83
7 An electron microscopic study of single-cycle infection of chick embryo fibroblasts by influenza virus. Virology 1969 1.65
8 Identification of a neutralization-specific antigen of a calf rotavirus. J Gen Virol 1982 1.64
9 New virus-specific antigens in cells infected with influenza virus. Virology 1969 1.48
10 Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol 1969 1.47
11 Defective interfering viruses and their potential as antiviral agents. Rev Med Virol 2010 1.44
12 Quantitative relationships between an influenza virus and neutralizing antibody. Virology 1987 1.37
13 Neutralization of animal virus infectivity by antibody. Arch Virol 2007 1.34
14 Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985 1.29
15 Electrophoretic separation of influenza virus ribonucleoproteins. J Gen Virol 1981 1.27
16 Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol 1994 1.26
17 A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 1997 1.24
18 Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J Gen Virol 1990 1.24
19 Biophysical studies of a rhinovirus. Extraction and assay of infectious ribonucleic acid. Nature 1966 1.19
20 Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology 1975 1.19
21 Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect 1991 1.12
22 Polyadenylic acid sequences in rhinovirus RNA species from infected human diploid cells. J Virol 1975 1.11
23 Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus. J Gen Virol 1978 1.09
24 The RNAs of defective-interfering influenza virus. Virology 1978 1.09
25 Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol 1994 1.08
26 Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. J Gen Virol 1982 1.07
27 Deletion analysis of a defective interfering Semliki Forest virus RNA genome defines a region in the nsP2 sequence that is required for efficient packaging of the genome into virus particles. J Virol 1998 1.07
28 Defective segment 1 RNAs that interfere with production of infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol 2002 1.06
29 A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol 2001 1.06
30 Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol 1997 1.05
31 Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol 2001 1.04
32 Heterologous protection of mice from a lethal human H1N1 influenza A virus infection by H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology 1998 1.04
33 Approximately 150 nucleotides from the 5' end of an influenza A segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology 2000 1.03
34 Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology 2000 1.02
35 Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates. J Gen Virol 1970 1.02
36 Characterization of putative defective interfering (DI) A/WSN RNAs isolated from the lungs of mice protected from an otherwise lethal respiratory infection with influenza virus A/WSN (H1N1): a subset of the inoculum DI RNAs. Virology 1995 1.02
37 Phosphorylation of influenza virus nucleoprotein in vivo. J Gen Virol 1981 1.01
38 Failure of an influenza virus to initiate infection in enucleate BHK cells. J Virol 1974 1.00
39 Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol 1992 1.00
40 Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 2000 0.99
41 Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses 1995 0.98
42 Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol 1990 0.98
43 Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 1996 0.98
44 Early events in influenza virus multiplication. II. Penetration of virus into cells at 4 degrees. Virology 1978 0.97
45 Fowl plaque virus replication in mammalian cell-avian erythrocyte heterokaryons: studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication. Virology 1974 0.96
46 Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J Gen Virol 1985 0.95
47 Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus. J Gen Virol 1989 0.95
48 Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. J Infect Dis 1997 0.95
49 Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol 1996 0.94
50 Replication of rhinovirus RNA. J Gen Virol 1973 0.94
51 Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 2006 0.94
52 Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. Virology 1980 0.94
53 Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift. Epidemiol Infect 1997 0.94
54 Common sequence elements in structurally unrelated genomes of defective interfering Semliki Forest virus. Virology 1994 0.93
55 High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol 1997 0.93
56 Location of influenza virus M, NP and NS1 proteins in microinjected cells. J Gen Virol 1985 0.93
57 Kinetics of synthesis of influenza virus ribonucleoprotein structures. J Gen Virol 1982 0.92
58 Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol 1986 0.91
59 Competitive binding of neutralizing monoclonal and polyclonal IgG to the HA of influenza A virions in solution: only one IgG molecule is bound per HA trimer regardless of the specificity of the competitor. Virology 1994 0.91
60 Temporal control of transcription of influenza virus RNA. Virology 1975 0.90
61 Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology 1977 0.90
62 One defective interfering particle per cell prevents influenza virus-mediated cytopathology: an efficient assay system. J Gen Virol 1988 0.90
63 Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 1999 0.89
64 IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology 1993 0.89
65 A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol 1993 0.88
66 A rapid method for the inactivation of virus infectivity prior to assay for interferons. J Virol Methods 1984 0.88
67 IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo. J Gen Virol 1989 0.88
68 Defective interfering particles of Semliki Forest virus are smaller than particles of standard virus. J Gen Virol 1984 0.87
69 All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J Gen Virol 1995 0.86
70 Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. J Gen Virol 2000 0.86
71 Mechanisms of neutralization of influenza virus by IgM. J Gen Virol 1985 0.86
72 Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. J Virol Methods 1996 0.85
73 Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 1998 0.85
74 Different patterns of polyadenylation of rhinovirus: specified RNA during multiplication in human aneuploid and diploid cells. J Gen Virol 1976 0.85
75 Rhinovirus RNA polymerase: products and kinetics of appearance in human diploid cells. J Virol 1974 0.85
76 The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 1998 0.84
77 RNA'S of influenza C virus strains. Arch Virol 1979 0.84
78 The effect of defective-interfering Semliki Forest virus on the histopathology of infection with virulent Semliki Forest virus in mice. J Infect Dis 1982 0.84
79 Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res 1993 0.83
80 Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of influenza A virus. J Gen Virol 1994 0.83
81 Early events in influenza virus infection. III. The formation of a nucleoplasmic ribonucleoprotein complex from the input virion. Virology 1978 0.83
82 Intracellular stability of the interfering activity of a defective interfering influenza virus in the absence of virus multiplication. Virology 1987 0.83
83 A preliminary study of physiological characteristics of temperature-sensitive mutants of influenza virus. J Gen Virol 1973 0.83
84 Defective interfering influenza virus inhibits immunopathological effects of infectious virus in the mouse. J Virol 1992 0.82
85 Subclinical infections in mice resulting from the modulation of a lethal dose of Semliki Forest virus with defective interfering viruses: neurochemical abnormalities in the central nervous system. J Gen Virol 1986 0.82
86 Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target. J Gen Virol 1996 0.82
87 Early events in influenza virus multiplication. I. Location and fate of the input RNA. Virology 1975 0.82
88 Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization. AIDS Res Hum Retroviruses 2001 0.82
89 Persistence of virulent Semliki Forest virus in mouse brain following co-inoculation with defective interfering particles. J Gen Virol 1986 0.82
90 Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions. Vaccine 1996 0.81
91 Assay of defective-interfering semliki forest virus by the inhibition of synthesis of virus-specified RNAs. J Gen Virol 1981 0.81
92 The genomic sequence of defective interfering Semliki Forest virus (SFV) determines its ability to be replicated in mouse brain and to protect against a lethal SFV infection in vivo. Virology 1998 0.81
93 Inhibition of the processing of ribosomal RNA in avian cells infected with an influenza virus. Biochim Biophys Acta 1974 0.81
94 Polymorphism of the NS1 proteins of type A influenza virus. J Gen Virol 1982 0.81
95 Heterogeneity of apparently empty poliovirus particles stained with phosphotungstic acid after heating of the virus at "low" temperature. Virology 1967 0.81
96 Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J Virol Methods 2003 0.81
97 Modulation of Semliki Forest virus-induced infection of mice by defective-interfering virus. J Infect Dis 1984 0.80
98 Modulation of a systemic Semliki Forest virus infection in mice by defective interfering virus. J Gen Virol 1984 0.80
99 Internal proteins of influenza virus: 35S-methionine peptide maps as genetic markers. J Gen Virol 1977 0.79
100 Mechanisms of neutralization of influenza virus in tracheal epithelial and BHK cells vary according to IgG concentration. Virology 1990 0.79
101 An influenza haemagglutinin-specific IgG enhances class I MHC-restricted CTL killing in vitro. Immunology 1991 0.79
102 Infection of chicken erythrocytes with influenza and other viruses. Infect Immun 1979 0.79
103 Protection of mice from lethal influenza by defective interfering virus: T cell responses. J Gen Virol 1992 0.79
104 Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines. J Med Virol 2001 0.78
105 A human CD4+ T-cell line expresses functional CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes. Immunology 1997 0.78
106 Intracellular stability of the gene encoding influenza virus haemagglutinin. Virology 1990 0.78
107 Increasing the efficiency of virus infectivity assays: small inoculum volumes are as effective as centrifugal enhancement. J Virol Methods 2001 0.78
108 Variation in homotypic and heterotypic interference by defective interfering viruses derived from different strains of Semliki Forest virus and from Sindbis virus. J Gen Virol 1984 0.78
109 Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. J Gen Virol 1999 0.78
110 The multiplication of influenza virus in enucleated BHK cells fused with chicken erythrocytes. Virology 1976 0.77
111 Influence of the host cell on the genomic and subgenomic RNA content of defective-interfering influenza virus. J Gen Virol 1981 0.77
112 Defective interfering Semliki Forest virus populations are biologically and physically heterogeneous. J Gen Virol 1984 0.77
113 The coupling of transcription from influenza virions to translation in vitro. Arch Virol 1979 0.77
114 Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralizing antibody escape mutant of human immunodeficiency virus type 1. Arch Virol 2001 0.77
115 The role of the neuraminidase of the infecting virus in the production of noninfectious (von Magnus) influenza virus. Virology 1970 0.76
116 Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry. Eur J Biochem 1998 0.76
117 Protection of mice infected with a lethal dose of Semliki Forest virus by defective interfering virus: modulation of virus multiplication. J Gen Virol 1984 0.76
118 Rhinovirus multistranded RNA: dependence of the replicative form on the presence of actinomycin D. J Virol 1976 0.75
119 Influence of the host cell on proteins synthesized by different strains of influenza virus. Virology 1979 0.75
120 Camptothecin: an inhibitor of influenza virus replication. J Gen Virol 1974 0.75
121 Mechanisms of neutralization of a nairovirus (Dugbe virus) by polyclonal IgG and IgM. J Gen Virol 1992 0.75
122 Differential effects of defective interfering Semliki Forest virus on cellular and virus polypeptide synthesis. Virology 1985 0.75
123 Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160. AIDS Res Hum Retroviruses 1994 0.75
124 Properties of host and virus which influence defective interfering virus mediated-protection of mice against Semliki Forest virus lethal encephalitis. Brief report. Arch Virol 1984 0.75
125 Adenylic acid - rich sequences in influenza virus RNA. Biochem Biophys Res Commun 1975 0.75
126 Neutralization titres of HIV-1-specific monoclonal antibodies vary according to the batch of primary human peripheral blood lymphocytes, but do not vary coordinately. J Virol Methods 1997 0.75
127 Newly synthesized influenza virus proteins are transported from the nucleus. J Gen Virol 1979 0.75
128 Processing of exogenous poly(A) added to virus-infected cells. Biochem Biophys Res Commun 1978 0.75
129 Complementation with an avian influenza virus is required for synthesis of M protein of a human strain in chicken erythocytes. Arch Virol 1980 0.75